Biostage names new chief financial officer
9 August 2022 -

Biostage Inc (OTCQB:BSTG), a US-based cell-therapy biotechnology company, announced on Monday that it has appointed Joseph Damasio as chief financial officer.

Damasio has served as CFO, VP Finance and controller at Inhibikase Therapeutics, Cue Biopharma and Pressure Biosciences. He has a BS in Accounting from the University of Massachusetts (Dartmouth), an MS in Finance from Boston College and an MBA from Boston College, and is a Massachusetts-licensed CPA, a former auditor with PricewaterhouseCoopers and served in the United States Navy.

David Green, Biostage's founder, chair of the board and interim chief executive officer said: "Joe's skills and experience will help Biostage with its intended relisting on NASDAQ, its future capital raises and its operational management as we prepare for our clinical trial in patients with severe oesophageal disease."